CTD Holdings, Inc. is a clinical stage biotechnology company that develops cyclodextrin based products for the treatment of diseases with unmet need. The company s Trappsol R Cyclo TM , an orphan drug designated product in the United States and the EU, is used to treat Niemann Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol R Cyclo TM are in development. For additional information, visit the company s website: www.ctd holdings.com
Quote | Ctd Holdings Inc (OTCMKTS:CTDH)
Last: | $0.086 |
---|---|
Change Percent: | 36.51% |
Open: | $0.066 |
Close: | $0.086 |
High: | $0.099 |
Low: | $0.0631 |
Volume: | 356,808 |
Last Trade Date Time: | 12/08/2020 04:54:47 pm |
News | Ctd Holdings Inc (OTCMKTS:CTDH)
Conference Brings Together Medical Researchers and Health Professionals to Exchange Information on Lysosomal Diseases Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases...
The FDA has signed-off Phase 3 trial evaluating Cyclo Therapeutics's ([[CTDH]] +8.0%) lead candidate Trappsol Cyclo (Hydroxypropyl-β-cyclodextrin), for the treatment of Niemann-Pick Disease Type C, a rare inherited disorder in which the body is unable to transport choles...
Message Board Posts | Ctd Holdings Inc (OTCMKTS:CTDH)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Ctd Holdings Inc Company Name:
CTDH Stock Symbol:
OTCMKTS Market:
Conference Brings Together Medical Researchers and Health Professionals to Exchange Information on Lysosomal Diseases Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases...
Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol ® Cyclo™ for treatment of Niemann-Pick Disease Type C Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for t...
Cyclo Therapeutics is proud to sponsor the conference for the 5 th consecutive year Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer...